Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registry.
Saved in:
| Title: | Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registry. |
|---|---|
| Authors: | Surcinelli A; Department of Neuroscience, Multiple Sclerosis Center, Neurology Unit, S. Maria delle Croci Hospital, AUSL Romagna, Viale Vincenzo Randi 5, Ravenna 48121, Italy., Kalincik T; Neuroimmunology Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia.; CORe, Department of Medicine, University of Melbourne, Melbourne, Australia., Roos I; Neuroimmunology Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia.; CORe, Department of Medicine, University of Melbourne, Melbourne, Australia., D'Amico E; Università di Foggia, Medical and Surgical Sciences, Foggia, Italy., Lechner-Scott J; University Newcastle, Newcastle, Australia.; Hunter New England Health, John Hunter Hospital, NSW Australia., Ozakbas S; Izmir University of Economics, Medical Point Hospital, Izmir, Turkey.; Multiple Sclerosis Research Association, Izmir Turkey., Hradilek P; Department of Neurology, University Hospital Ostrava, Ostrava, Czech Republic., Horáková D; Charles University in Prague and General University Hospital, Prague, Czech Republic., Vachova M; Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.; Department of Neurology, KZ a.s., Hospital Teplice, Teplice, Czech Republic., Panzera I; Department of Neuroscience, Multiple Sclerosis Center, Neurology Unit, S. Maria delle Croci Hospital, AUSL Romagna, Ravenna, Italy., Ruzza S; Department of Neuroscience, Multiple Sclerosis Center, Neurology Unit, S. Maria delle Croci Hospital, AUSL Romagna, Ravenna, Italy., Piscaglia MG; Department of Neuroscience, Multiple Sclerosis Center, Neurology Unit, S. Maria delle Croci Hospital, AUSL Romagna, Ravenna, Italy., Gerlach O; Academic MS Center Zuyd, Department of Neurology, Zuyderland Medical Center, Sittard-Geleen, The Netherlands.; School for Mental Health and Neuroscience, Department of Neurology, Maastricht University Medical Center, Maastricht, The Netherlands., Meca-Lallana JE; Multiple Sclerosis CSUR and Clinical Neuroimmunology Unit, Neurology Department, Virgen de la Arrixaca Clinical University Hospital (IMIB-Arrixaca) and NICEM Cathedra-UCAM-San Antonio Catholic University, Murcia, Spain.; NICEM Cathedra. UCAM-San Antonio Catholic University, Murcia, Spain., Valero-López G; Multiple Sclerosis CSUR and Clinical Neuroimmunology Unit, Neurology Department, Virgen de la Arrixaca Clinical University Hospital (IMIB-Arrixaca) and NICEM Cathedra-UCAM-San Antonio Catholic University, Murcia, Spain.; NICEM Cathedra. UCAM-San Antonio Catholic University, Murcia, Spain., Kermode AG; Perron Institute for Neurological and Translational Science, Sir Charles Gairdner Hospital, QEIIMC, University of Western Australia, Nedlands, Australia.; Personalised Medicine Centre, Health Futures Institute, Murdoch University, Western Australia.; Institute for Immunology and Infectious Diseases, Murdoch University, Perth, Western Australia, Australia., Fabis-Pedrini MJ; Perron Institute for Neurological and Translational Science, Sir Charles Gairdner Hospital, QEIIMC, University of Western Australia, Nedlands, Australia.; Personalised Medicine Centre, Health Futures Institute, Murdoch University, Western Australia., Prevost J; CSSS Saint-Jérôme, Saint-Jerome, Canada., Ampapa R; Nemocnice Jihlava, Jihlava, Czech Republic., Hodgkinson S; Liverpool Hospital and UNSW and Ingham Institute Liverpool, Australia., Grand'Maison F; Neuro Rive-Sud, Quebec, Canada., Khoury SJ; American University of Beirut Medical Center, Beirut, Lebanon., John NA; Monash University, Clayton, Australia.; Department of Neurology, Monash Health, Clayton, Australia., Peterka M; Department of Neurology, Faculty of Medicine in Pilsen, Charles University and University Hospital Pilsen, Pilsen, Czech Republic.; Faculty of Medicine in Hradec Kralove, Charles University and University Hospital Hradec Kralove, Hradec Kralove, Czechia., Houskova J; Department of Neurology, Hospital Ceske Budejovice, Ceske Budejovice, Czech Republic., Recmanova E; Department of Neurology, Tomas Bata Regional Hospital, Zlin, Czech Republic., Rous Z; Department of Neurology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic., Shaygannejad V; Isfahan University of Medical Sciences(IUMS), Isfahan Neurosciences Research Center (INRC), Iran., Alroughani R; Amiri Hospital, Sharq, Kuwait., Kuhle J; University Hospital and University of Basel, Basel, Switzerland.; Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland., Jakob GB; Department of Neurology, University Medical Centre Ljubljana, Slovenia.; Faculty of Medicine, University of Ljubljana, Slovenia., Grammond P; CISSS Chaudière-Appalache, Levis, Canada., Patti F; Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Catania, Italy.; Multiple Sclerosis Unit, AOU Policlinico G Rodolico-San Marco, University of Catania, Catania, Italy., Van der Walt A; Department of Neurology, The Alfred Hospital, Melbourne, Australia.; Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Australia., Butzkueven H; Department of Neurology, The Alfred Hospital, Melbourne, Australia.; Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Australia., Foschi M; Department of Neuroscience, Multiple Sclerosis Center, Neurology Unit, S. Maria delle Croci Hospital, AUSL Romagna, Ravenna, Italy.; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy. |
| Source: | Therapeutic advances in neurological disorders [Ther Adv Neurol Disord] 2026 Mar 26; Vol. 19, pp. 17562864261430084. Date of Electronic Publication: 2026 Mar 26 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: SAGE Country of Publication: England NLM ID: 101480242 Publication Model: eCollection Cited Medium: Print ISSN: 1756-2856 (Print) Linking ISSN: 17562856 NLM ISO Abbreviation: Ther Adv Neurol Disord Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1756-2856 |
|---|---|
| DOI: | 10.1177/17562864261430084 |
